Y 27632

Drug Profile

Y 27632

Latest Information Update: 17 Nov 2009

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Kyushu University; Medical College of Georgia; Mitsubishi Tanabe Pharma Corporation; Vanderbilt University School of Medicine
  • Class Antiasthmatics; Antihypertensives; Muscle relaxants
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Asthma; Cardiovascular disorders; Erectile dysfunction; Hypertension

Most Recent Events

  • 17 Nov 2009 Discontinued - Preclinical for Hypertension in Japan (unspecified route)
  • 17 Nov 2009 Discontinued - Preclinical for Erectile dysfunction in USA (unspecified route)
  • 17 Nov 2009 Discontinued - Preclinical for Cardiovascular disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top